|Structural Type:||[ ]|
|Functional Type:||[ ]|
Shared Reference Notes
- [1.1] [#Inflamatory bowel disease]
- Gut metagenomic profiles of patients with inflammatory bowel disease (IBD) are highly correlated with fecal calprotectin levels, a biomarker for severity of inflammation in IBD.
- [1.2] [#Parkinson’s Disease]
- detection of calprotectin, a faecal marker of inflammation by ELISA, may be helpful in detecting early signs of the activated colonic immune system in PD
- [1.3] [#Parkinson’s Disease]
- Other possible inflammatory markers of PD are calprotectin and #Zonulin. - The first is a marker of inflammation, while the second is a junction protein, which, if modulated by proinflammatory signals (e.g., LPS), can lead to an increase in intestinal membrane permeability. - both fecal and serum levels of calprotectin and #Zonulin are elevated in patients with PD
- [1.4] [#Multiple Sclerosis]
- fecal #Lipocalin-2 (Lcn-2), a biomarker of intestinal inflammation, was significantly elevated and predominantly produced by the gut-infiltrating neutrophils. - The elevation of fecal Lcn-2 levels correlated with reduced bacterial diversity and increased levels of other intestinal inflammation markers including neutrophil elastase and calprotectin.
- cCLP as a key molecule of inflammation, which is not synthesized in the liver but produced by activated neutrophils in damaged tissues.
- - High cCLP serum levels are associated with worse structural outcomes in #Rheumatoid Arthritis and to a lesser extent, in #Spondyloarthritis.